Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Technology Holistically Images Deep Living Tissue for The First Time

By LabMedica International staff writers
Posted on 16 Sep 2024

Tissue engineering involves the restoration or enhancement of cell and tissue function in the body by replacing defective counterparts with lab-grown ones. More...

This technique holds promise for a wide range of applications, such as cultivating cartilage to transplant into a patient's damaged knee. Since cartilage cannot regenerate itself, damage to it is a leading cause of osteoarthritis. The composition of transplanted cells and tissues is crucial for acceptance by the body. If the internal composition is compromised, there is a higher likelihood of rejection or poor function. This is particularly true for the extracellular matrix—the space between cells that determines cell structure and intercellular communication. Traditional imaging methods like fluorescence microscopy have used fluorescent labels to tag specific molecules within cells. However, these labels provide a limited view by gathering information only from tagged molecule groups and can be toxic, preventing the tissue from being suitable for transplantation.

In tissue engineering, this necessitates growing two sets of tissue cultures in the lab before transplantation into the body: one for examination to ensure the sample is safe and another for the actual transplant. This process is costly, and significant variability in the quality of lab-grown cell compositions means that even if scientists image a sample produced under the same conditions as the one intended for transplantation, they cannot be certain it will not be rejected. Now, a new device that uses light to non-destructively image tissue could revolutionize cartilage and tissue transplant treatments, laying the groundwork for osteoarthritis therapy.

Developed through collaborative research that included investigators from King's College London (London, UK), this new device is the first of its kind to reveal the molecular structure of deep tissue without relying on limiting fluorescent labels. Detailed in Nature Communications, this readily available machine could enhance the use of tissue engineering in medicine and halve the costs of tissue production in the lab. The researchers' approach, Raman Spectral Projection Tomography, builds on previous technologies that use light to provide a clear and non-invasive view at much deeper levels than before, allowing for the assessment of the extracellular matrix.

The composition of most lab-grown cartilage shows varying levels of vital components in the extracellular matrix, like collagen. Without the ability to see this variation, scientists cannot be certain that the tissues they transplant into the body will be safe and functional, making improvements to individual samples slow and iterative. By imaging such tissues without harming the cells, researchers will, for the first time, be able to have confidence that a transplant will work at half the cost. In the future, the team hopes to use this technology in operating theaters to image tumors in patients undergoing surgical removal, reducing the need for time-consuming study of tumor tissues while potentially saving time and lives.

“Tissue engineering has the potential to be life changing for many patients. Approximately, one in five people aged 45 suffer from osteoarthritis in the UK, and cartilage in the knee has no way of replacing itself. Transplantation with tissue engineered constructs could help solve that,” said Dr. Mads Bergholt, Reader in Biophotonics at King’s College London.

Related Links:
King’s College London


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.